產品詳情
簡單介紹：
Anti-LAP1抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-LAP1抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-LAP1
Cat. Number:
Anti-LAP1抗體KL-11351R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Densin-180 is a synaptic transmembrane protein that is tightly associated with the postsynaptic density in CNS neurons and is postulated to function as a synaptic adhesion molecule. Densin-180 is a brain-specific momber of the Anti-LAP1抗體O-sialoglycoprotein family which is highly concentrated at synapses along dendrites. The sequence of densin-180 contains 17 leucine-rich repeats, a sialomucin domain, an apparent transmembrane domain, and a PDZ (PSD-95, DIg, Z0-1) domain. The PDZ domain contributes to its binding to a-actinin. The intracellular portion of densin-180, CaMKIIa, interacts with a-actinin at distinct binding sites and, together, they form a ternary complex stabilized by multiple interactions.
Also known as:
Densin 180; Densin; Densin-180; Anti-LAP1抗體densin180; DKFZp686I1147; KIAA1365; Lamin associated polypeptide 1; LAP 1; Leucine rich repeat containing 7; Leucine rich repeat containing protein 7; Leucine-rich repeat-containing protein 7; Lrrc 7; Lrrc7; LRRC7_HUMAN; MGC144918; OTTHUMP00000065336; OTTHUMP00000065337; OTTHUMP00000065338; Protein Lap 1; Protein lap1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human Densin18.
●
Predicted Molecular Weight: Anti-LAP1抗體173kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-LAP1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-LAP1抗體
Optimal working dilutions must be determined by the end user.
